Skip to main content

QIAGEN N.V.

corporate_fare Company Profile

QIAGEN N.V.

QGEN·NYSE·Life Sciences·CIK 0001015820

Qiagen N.V. provides "sample to insight" solutions globally, transforming biological samples into molecular insights for the molecular diagnostics and life sciences sectors. The company offers sample technology consumables, including nucleic acid stabilization and purification kits for various sample materials, supporting manual and automated processing for genotyping, gene expression, and viral and bacterial analysis. These consumables utilize silica membranes and magnetic bead technologies. It also provides secondary sample technology consumables for nucleic acid purification and instruments for nucleic acid purification and quality control. Qiagen's product portfolio includes Immune response consumables, such as interferon-gamma release assays for TB testing, and assays for post-transplant testing and viral load monitoring. For oncology and sexual and reproductive health, it offers assays for prenatal testing, detection of sexually transmitted diseases and HPV, and analysis of genomic variants. The company also provides "sample to insight" instruments for one-step molecular analysis of hard-to-diagnose syndromes and integrated PCR testing. Additionally, Qiagen offers research PCR consumables, including quantitative PCR, reverse transcription, and combination kits for gene expression, genotyping, and gene regulation, compatible with QIAGEN instruments. Its human ID/forensics assay consumables include short tandem repeat assays for human identification and assays for food contamination. The company provides PCR instruments, such as digital PCR and qPCR solutions, along with developed and configured enzymes and PCR solutions. Further offerings include NGS gene panels, library prep kits and components, whole genome amplification, DNA methylation analysis, QIAGEN consumables and instruments, bioinformatics solutions, sequence-based assays, forensic genetic genealogy services, and software-as-a-service. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

QIAGEN N.V. (NYSE:QGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for QGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for QGEN spans SC14D9C, 6-K, 20-F.

Recent high-impact activity:

  • Qiagen Beats Q3 Outlook, Suspends 2026 Guidance Pending EQT Takeover
  • QIAGEN Board Accepts EQT's €46.50/Share Takeover, Valuing Company at $12.1B
  • QIAGEN Signs Definitive EQT Deal at €46.50/Share; Q3 Sales $548M, FY26 Outlook Suspended
  • EQT Nears €9.6B Takeover of Qiagen at €46.50 a Share; Board Approval Could Come Wednesday
  • EQT in Advanced Talks to Buy Qiagen With Binding Offer Above $50/Share

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.09B
Net Income
$424.88M
Diluted EPS
$1.94
Op. Cash Flow
$654.33M
Free Cash Flow
$453.28M
Gross Profit
$1.3B
Operating Income
$465.85M
Cash & Equivalents
$839M
Total Debt
$1.65B
Debt / Equity
0.44×
Net Margin
20.3%
Shares Outstanding
217.22M sh
Source: 20-F · filed 2026-03-20 · accession 0001015820-26-000018

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 6,404,422 shares in QGEN as of the October 30, 2026 settlement, a 11.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 64.6% of QGEN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,404,422 shares as of October 30, 2026
Change vs prior period▼ 11.1%
Days to cover1.00 at avg daily volume of 8,673,760
Daily short volume (FINRA facilities)64.6% of 1,164,792 shares on November 20, 2026
5-day average short volume42.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

QGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with Q →
$49.3
52-week range · as of 2026-10-21 $32.53 – $57.81
Market cap
$10.18B
Volume
2.6M (0.5× avg)
3-mo avg 5.2M
Live data · 2026-11-21 07:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed QGEN - Latest Insights

QGEN
Nov 04, 2026, 4:17 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $50.90
Real-time Price: $49.30 info
Change: -$1.60 (-3%) info
Market Cap: $10.18B info
QGEN
Oct 22, 2026, 1:35 AM EDT
Source: dpa-AFX
Importance Score:
9
Price at Filing: $50.27
Real-time Price: $49.30 info
Change: -$0.970 (-2%) info
Market Cap: $10.18B info
QGEN
Oct 21, 2026, 6:11 PM EDT
Filing Type: SC14D9C
Importance Score:
9
Price at Filing: $50.65
Real-time Price: $49.30 info
Change: -$1.35 (-3%) info
Market Cap: $10.18B info
QGEN
Oct 21, 2026, 3:52 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $49.97
Real-time Price: $49.30 info
Change: -$0.670 (-1%) info
Market Cap: $10.18B info
QGEN
Oct 20, 2026, 12:45 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $49.30
Real-time Price: $49.30 info
Change: $0 (0%) info
Market Cap: $10.18B info
QGEN
Sep 28, 2026, 1:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $44.18
Real-time Price: $49.30 info
Change: +$5.12 (+12%) info
Market Cap: $10.18B info
QGEN
Sep 17, 2026, 9:27 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.87
Real-time Price: $49.30 info
Change: +$5.43 (+12%) info
Market Cap: $10.18B info
QGEN
Sep 08, 2026, 7:45 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $42.01
Real-time Price: $49.30 info
Change: +$7.29 (+17%) info
Market Cap: $10.18B info
QGEN
Aug 28, 2026, 2:40 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $43.27
Real-time Price: $49.30 info
Change: +$6.03 (+14%) info
Market Cap: $10.18B info
QGEN
Aug 10, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.85
Real-time Price: $49.30 info
Change: +$5.45 (+12%) info
Market Cap: $10.18B info
QGEN
Aug 06, 2026, 6:37 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $42.42
Real-time Price: $49.30 info
Change: +$6.88 (+16%) info
Market Cap: $10.18B info
QGEN
Aug 05, 2026, 6:21 PM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $39.07
Real-time Price: $49.30 info
Change: +$10.23 (+26%) info
Market Cap: $10.18B info
QGEN
Jul 09, 2026, 10:20 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $42.43
Real-time Price: $49.30 info
Change: +$6.87 (+16%) info
Market Cap: $10.18B info
QGEN
May 07, 2026, 8:04 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $33.46
Real-time Price: $49.30 info
Change: +$15.84 (+47%) info
Market Cap: $10.18B info
QGEN
Mar 19, 2026, 9:11 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $40.33
Real-time Price: $49.30 info
Change: +$8.97 (+22%) info
Market Cap: $10.18B info
QGEN
Feb 05, 2026, 9:18 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.23
Real-time Price: $49.30 info
Change: -$1.93 (-4%) info
Market Cap: $10.18B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets